Voreloxin is primarily investigated for its potential in cancer treatment, particularly in targeting acute myeloid leukemia (AML), ovarian cancer, and other solid tumors. It functions as a topoisomerase II inhibitor, disrupting DNA replication and leading to cancer cell death. Its unique mechanism of action allows it to induce DNA damage selectively in rapidly dividing cancer cells, making it a promising candidate for therapeutic use. Clinical trials have explored its efficacy and safety, focusing on its ability to improve outcomes in patients with relapsed or refractory AML and platinum-resistant ovarian cancer. Additionally, research is ongoing to evaluate its potential in combination therapies to enhance its anticancer effects. It is administered intravenously under medical supervision, with potential side effects including myelosuppression and nausea.